EPISODE · Sep 6, 2022 · 18 MIN
Precision therapeutics can individualize depression treatment: Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D.
from Answers from the Lab · host Mayo Clinic Laboratories
(00:31) Can you both tell us a little bit about yourselves and your backgrounds? Dr. Moyer, do you want to start?(01:51) Your background, Dr. Janetto?(02:47) Please provide an overview of major depressive disorder and the test that Mayo Clinic Laboratories has available for therapeutic drug monitoring as well as pharmacogenomics.(07:05) Which patients should have this testing, and when should it be performed? (11:33) What alternative test options are available, and how do they compare?(15:37) How are the results used in patient care?
Embed this episode
What this episode covers
Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic testing and therapeutic drug monitoring can guide clinicians to choose the most-effective treatment for each patient.
NOW PLAYING
Precision therapeutics can individualize depression treatment: Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D.
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.